Participant flow

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) · Source last updated 2023-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.

   id

   FG000

   title

   Lisocabtagene Maraleucel (JCAR017)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Other reasons

   2. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      No longer meets eligibility criteria

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Disease-related complications

   4. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         74

      comment

      Participants who underwent leukapheresis

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         63

      comment

      Participants who completed leukapheresis and continued to lymphodepleting chemotherapy (LDC) treatment period

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      NOT COMPLETED

   title

   Pre-Treatment Phase

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Other reasons

   3. reasons

      1. group Id

         FG000

         num Subjects

         23

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Did not receive either JAR017 or nonconforming product

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Received nonconforming product

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         63

      comment

      Participants who underwent lymphodepleting chemotherapy (LDC) treatment

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         61

      type

      Received JCAR017

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      Received Nonconforming Product

   4. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      Did Not Receive Either JAR017 or Nonconforming Product

   5. achievements

      1. group Id

         FG000

         num Subjects

         30

      comment

      Completed study

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         33

      type

      NOT COMPLETED

   title

   Treatment Phase

pre Assignment Details

All efficacy and safety analyses were conducted on the JCAR017-treated Analysis Set.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice